WallStSmart

Amphenol Corporation (APH)vsIQVIA Holdings Inc (IQV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Amphenol Corporation generates 42% more annual revenue ($23.09B vs $16.31B). APH leads profitability with a 18.5% profit margin vs 8.3%. IQV appears more attractively valued with a PEG of 0.97. APH earns a higher WallStSmart Score of 76/100 (B+).

APH

Strong Buy

76

out of 100

Grade: B+

Growth: 10.0Profit: 9.0Value: 8.7Quality: 6.8
Piotroski: 4/9Altman Z: 2.36

IQV

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 10.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

APHUndervalued (+6.8%)

Margin of Safety

+6.8%

Fair Value

$156.78

Current Price

$128.73

$28.05 discount

UndervaluedFair: $156.78Overvalued
IQVUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$348.46

Current Price

$165.64

$182.82 discount

UndervaluedFair: $348.46Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

APH6 strengths · Avg: 9.2/10
Return on EquityProfitability
36.8%10/10

Every $100 of equity generates 37 in profit

Revenue GrowthGrowth
49.1%10/10

Revenue surging 49.1% year-over-year

EPS GrowthGrowth
57.6%10/10

Earnings expanding 57.6% YoY

Market CapQuality
$157.29B9/10

Large-cap with strong market position

Operating MarginProfitability
27.5%8/10

Strong operational efficiency at 27.5%

Free Cash FlowQuality
$1.47B8/10

Generating 1.5B in free cash flow

IQV3 strengths · Avg: 8.3/10
Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

EPS GrowthGrowth
23.6%8/10

Earnings expanding 23.6% YoY

Areas to Watch

APH2 concerns · Avg: 4.0/10
P/E RatioValuation
38.2x4/10

Premium valuation, high expectations priced in

Price/BookValuation
11.8x4/10

Trading at 11.8x book value

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : APH

The strongest argument for APH centers on Return on Equity, Revenue Growth, EPS Growth. Profitability is solid with margins at 18.5% and operating margin at 27.5%. Revenue growth of 49.1% demonstrates continued momentum.

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bear Case : APH

The primary concerns for APH are P/E Ratio, Price/Book.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Key Dynamics to Monitor

APH profiles as a growth stock while IQV is a value play — different risk/reward profiles.

IQV carries more volatility with a beta of 1.41 — expect wider price swings.

APH is growing revenue faster at 49.1% — sustainability is the question.

APH generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

APH scores higher overall (76/100 vs 72/100), backed by strong 18.5% margins and 49.1% revenue growth. IQV offers better value entry with a 49.1% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Amphenol Corporation

TECHNOLOGY · ELECTRONIC COMPONENTS · USA

Amphenol Corporation is a major producer of electronic and fiber optic connectors, cable and interconnect systems such as coaxial cables. Amphenol is a portmanteau from the corporation's original name, American Phenolic Corp.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Want to dig deeper into these stocks?